

Research Article

A Novel Structural Modification Strategy to Incorporate LAT-1 Transporter Inhibitory Activity

Li L¹, Li Y², Gong M² and Zhang B^{1*}¹School of Chemical Engineering and Technology, Tianjin University, 135 Yaguan Road, Jinnan District, Tianjin, China²Tianjin Medical University General Hospital, Tianjin, China***Corresponding author:** Bao Zhang, School of Chemical Engineering and Technology, Tianjin University, 135 Yaguan Road, Jinnan District, Tianjin, China**Received:** February 23, 2020; **Accepted:** April 06, 2020; **Published:** April 13, 2020**Abstract**

L-type amino acid transporter 1 (LAT-1), overexpressed on the membrane of various tumor cells, was considered as a potential target for solid tumor therapy. It was hypothesized that conjugating a LAT-1 affinity molecule upon cell toxic agent could enhance the tumor targeting. In this study, quercetin was modified by overhanging a LAT-1 affinity group, with the aim of developing an effective LAT-1-mediated chemotherapeutic agent. On the other hand, the poor water solubility of quercetin limited its clinical utility in fact, this obstacle was ameliorated by conjugating the LAT-1 affinity group.

The anti-tumor assays in this study ascertained that the novel compound possessed LAT-1 inhibitory activity in high affinity which lead to progress of anti-tumor activity of quercetin, and increase on water-solubility of quercetin which enhanced the bioavailability of quercetin. All those data suggested that chem-conjugating a LAT-1 affinity group with traditional cellular toxic agent might be a powerful approach aiming to re-utilize and ameliorate its original anti-tumor characterizations.

Keywords: Quercetin; LAT-1 transporter; Solubility**Introduction**

The amino acid transporters on the plasma membrane is crucial for mediating the amino acid transportation in and out of cells and organelles which is essential for cellular physiological function [1]. The L-type amino acid transporter-1 (LAT-1), a Na⁺-independent neutral amino acid transporter [2,3] which has been identified as potential as a target for tumor therapy since LAT-1 transporters is not only overexpressed in various tumor cells but also in organ barrier system including blood brain barrier, testis barrier and placental barrier. The existence of these barriers extremely decreased the drug bioavailability following the lesion in drug efficacy [4-6].

Quercetin (3,3',4',5,7-pentahydroxyflavone), a natural flavonoid found in various vegetables and fruits, was reported to possess anti-carcinogenic properties against a wide range of human cancer [7,8]. It was ascertained that this compound plays its effects by inhibiting tyrosine kinases involved in cell signaling pathways, including HMGB1, JAK-STAT, and TSLP [9,10]. Following its comprehensive characterization, quercetin has been approved by FDA A as a therapeutic medicine for the treatment of prostatic cancer.

However, the poor water solubility of quercetin limited the efficacy in clinical utility of quercetin, the maximal solubility of quercetin of 0.1mg/ml even in 100% DMSO solution.

In this study, quercetin was conjugated with various amino acids possessing high affinity to the LAT-1 transporter containing a hydrolysis linker, with a view to enhancing affinity to LAT-1 overexpressed on tumor cells and water solubility relative to parent quercetin. The increased water solubility induced by the introduced amino acid led to improved bioavailability. Moreover, as expected, the derivatives synthesized in this study possessed higher LAT-1


affinity, which facilitated increased quercetin transport into tumor cells.

Materials and Methods**Reaction Scheme for synthesis of compound 2 (Scheme 1)**

Step 1: A suspension of starting material (0.9g, 1.36mmol, 1 eq), 2-bromoacetic acid (940mg, 6.79mmol, 5 eq), K₂CO₃ (1.5g, 10.86mmol, 8 eq), and NaI (40mg, 0.27, 0.2 eq) in EtOH (50mL) was refluxed overnight. The solvent was removed under vacuum and the residue re-dissolved in a mixture of ethyl acetate/water. HCl (2 N) was added to neutralize the mixture until pH reached 2-3. The desired product was extracted twice with EA. After drying and concentration, the residue was purified using silica gel column chromatography (Pure PE/EA = 2/1 to DCM/MeOH=20/1) to obtain target compound as a yellow solid (0.9g, 92%).

Step 2: The starting material (4.2g, 17mmol, 1 eq) was dissolved in H₂O/CH₃CN (50/50 mL). Na₂CO₃ (1.81g, 17.05mmol, 1 eq) was added and stirred to dissolve into the mixture. TrocCl was added (3.97, 18.76, 1.1 eq) within 15min and further stirred for 4h at room temperature. LC-MS analysis revealed the formation of an intermediate, which was reacted with BnBr (3.21g, 18.76, 1.1 eq). The mixture was warmed to 50°C and stirred for an additional 4h. EA was added to the reaction mixture, the organic phase separated, and the aqueous layer extracted once with EA. The combined organic phase was dried and concentrated. The residue obtained was purified directly via silica gel column chromatography (PE/EA = 8/1 to 5/1) to obtain the target compound as a colorless oil (4.88g, 56%).

Step 3: The starting material (4.88g, 9.53mmol, 1 eq) was dissolved in a solution of EtOH/AcOH (60/2 mL). Zn powder (6.23g,



95.3mmol, 10 eq) was added and the mixture stirred for 0.5h at rt. The reaction suspension was filtered and washed with MeOH. The filtrate was concentrated under vacuum and re-dissolved in a mixture of DCM/water. After separation of the DCM phase, the aqueous phase was extracted once with DCM. The combined organic layer was dried and concentrated, and the residue further purified using a silica gel column [DCM/MeOH = 20/1 to 10/1 to 5/1(3% NH₃)] to obtain target material as a yellow oil (1.4g, 46%).

Step 4: The starting acid material (502mg, 0.7mmol, 1 eq), EDC (336mg, 2.09mmol, 3 eq), and HOBT (292mg, 2.09mmol, 3 eq) were dissolved in dry DCM (30ml) and stirred for 5min, followed by the addition of DIPEA (280mg, 2.09mmol, 3 eq) and amino compound (291mg, 0.84mmol, 1.2 eq). The mixture was stirred for 16h at rt and the reaction mixture concentrated. The residue was re-dissolved in EA and washed once with HCl, once with Na₂CO₃, and once with brine. After drying and removal of solvent, the residue was purified using column chromatography (PE/EA=2/1 to 3/2) to obtain TM as a yellow oil (600mg, 73%).

Step 5: The starting material (600mg, 0.58mmol) was dissolved in DCM (10mL). After addition of TFA (3mL), the mixture was stirred for 30min at rt. Next, the solvent and TFA were removed, and the residue re-dissolved in DCM (20mL). A Na₂CO₃ aqueous solution (20mL) was added and the mixture stirred for 15min. The DCM layer was separated, dried, and concentrated. The residue was purified using silica-gel column chromatography (PE/acetone= 2/1 to DCM/MeOH =15/1, 0.5% NH₃) and TM obtained as a yellow oil (488mg, 90%).

Step 6: SM (150mg) was dissolved in THF and Pd/C (10%, 200mg) added under a hydrogen atmosphere, and stirred for 6h. Then the residue was dissolved into DMSO and filtered to obtain a DMSO

solution of the desired compound. The solution was purified directly using reverse C18 column chromatography (CH₃CN/H₂O = 90/1 to 80/20, 3% NH₃HCO₃) to obtain TM as a yellow solid (65mg, 83%).

The Mass spectrum and NMR spectrum of this compound was showed in supplementary Figure 1.

Reaction Scheme for synthesis of compound 3 (Scheme 2)

Step 1: To a solution of SM (1g, 1.5mmol, 1 eq), alcohol (818mg, 2.26mmol, 1.5 eq), and PPh₃ (790mg, 3.02mmol, 2 eq) in dry THF (30mL), DIAD was added (0.61mL, 3.02mmol, 2 eq) at rt. The mixture was stirred for 10min and warmed to 60°C for 3h. Following removal of solvent under vacuum, the residue was purified directly via silica gel column chromatography (pure DCM to DCM/MeOH = 200/1) to obtain the target compound as a yellow oil (1g, 66%).

Step 2: The starting material (1g, 1mmol) was dissolved in DCM (10mL), followed by sequential addition of TFA (3mL) and Et₃SiH (0.3mL). The mixture was stirred for 45min at rt and concentrated under vacuum. After re-dissolving the residue in DCM (50mL), aqueous saturated Na₂CO₃ (50mL) was added and stirred for 10min. The DCM phase was separated, dried over anhydrous Na₂SO₄, and concentrated. The generated residue was purified using silica gel column chromatography (PE/EA = 2/1 to DCM/MeOH =40/1) to obtain the target compound as a yellow oil (0.6g, 79%).

Step 3: The starting material (0.6g, 0.78mmol) was dissolved in THF/MeOH (4/4 mL) solution, followed by addition of NaOH aqueous solution (2mL, 2N). After stirring the mixture for 2h at rt, TFA was added to neutralize the reaction solution. Next, the solution was concentrated under vacuum and a mixture of MeOH/H₂O (~1/1) added to partly re-dissolve the residue. The resultant suspension was purified using reverse C-18 column chromatography [CH₃CN/H₂O =





Figure 1: Cellular uptake assay.

1A) Measurement of the transporting rate of compound 2 by LAT1-1; 1B) Measurement of the relative transportation efficiency of compound 2; 1C) Q2 was competitive inhibitor against LAT-1 transporter.

The result indicated that the compound 2 (Q2) exhibited LAT-1 inhibitory characterization, and the transportation rate was saturated in 15 minutes.

Reaction scheme



Scheme 2:




Figure 2: Anti-tumor efficacy of compound 2 on human tumor bearing mice.

Panel A: Effect of compound 2 on human xenograft tumor model mice bearing A549 cells.

Panel B: Anti-tumour effect of the compound 2 in tumor-bearing mice.

Condition: Xenograft mice bearing A549 cells were treated with the quercetin and compound 2, respectively. The antitumor efficacy of compound 2 and quercetin was measured by monitoring the tumor volume after treatment from tumor bearing mice. Survival time was recorded in days after tumour injection. All data obtained for repeated experiments were pooled and utilised for statistical analysis.

Legend: Results indicated that tumor size possessed more reduction in group treated with compound 2 than those treated with quercetin in A549 bearing mice. In addition, the group treated with the compound 2 (●) exhibited efficient anti-tumor activity as shown. Experimental animals showed an improved survival time compared to quercetin (□), $p < 0.05$ ($n = 10$).

20/80 (0.3% TFA) to 75/25 (0.3% TFA)] to obtain TM (0.55g, 94%) as a yellow oil.

Step 4: The starting material (0.55g, 0.73mmol) was dissolved in dry DCM and cooled to -78°C . BBr₃ (2.4g, 10mmol, 13 eq) was added to the mixture, and the suspension stirred for 20min at -78°C and warmed to rt for an additional 30min. The reaction was quenched with water, DCM removed, and the aqueous solution purified directly using the reverse C-18 column (pure H₂O to CH₃CN/H₂O of 10/90 to pure H₂O to 0.3% ammonia aqueous solution). Purified TM was obtained as a yellow solid (142mg, 51%).

The purity of original compounds 2 and 3 was assessed via high-performance liquid chromatography (HPLC) and stored as a powder at -20°C .

Water solubility measurement

Quercetin, compounds 2 and 3 were weighed and dissolved into 0.9% NaCl, PBS and Hanks solution (pH 6.5 and 7.4). Quantitative measurement of samples was performed via LC-MS/MS.

Cellular uptake analysis of quercetin and modified compounds *in vitro*

The lung cancer cell line, A549, expresses high levels of LAT-1, supporting the utility of these cells for our experiments. Initially, the time-dependent cellular uptake of chemicals in A549 cells was investigated.

A549 cells were cultured in the medium at a density of 2.0×10^5 cells/mL, followed by inoculation into 24-well cell culture plates (1mL/well). After 48h cultured at 37°C and 5% CO₂, the medium was removed. Cells were washed with PBS and treated with test compound and control (quercetin) (25 μM) in PBS for 1, 2, 5, and 15 min, respectively. The reaction was terminated by washing three times with cold PBS solution, followed by addition of 300 μL methanol to each well. Liquid solution (50 μL) was removed, mixed with ddH₂O (50 μL), methanol (50 μL), and IS solution (50 μL), and analyzed using LC-MS/MS.

Inhibition assay of modified quercetin against LAT-1

The uptake assay was performed on A549 cells cultured at 37°C and 5% CO₂ in 24-well plates for 48h. Cell groups were incubated with test compounds (quercetin and compound 2 (Q2), negative control (JPH203; $-3 \mu\text{M}$), and positive control (JPH203; $-0.3 \mu\text{M}$). After removal of culture medium, cells were washed with PBS. Following incubation with warm PBS for 10min, cells were treated with either radioactive-labeled or non-labeled leucine for 2min. After termination of the reaction with cold PBS, cells were incubated with lysis solution (0.1M NaOH). Lysates were mixed with 3ml ULTIMA Gold scintillation solution and analyzed using the Tri-Carb 2910TR liquid scintillation counter. Ki values were calculated using the Lineweaver-Burk equation.

MTT assay

Cells were seeded in 96-well flat-bottom microtiter plates at a density of 5×10^4 cells per well and allowed to adhere overnight. Next, cells were treated with quercetin or compound 2 (final concentration of 10 $\mu\text{g}/\text{mL}$) for 24, 48, and 72 h. Simultaneously, control and zero-adjustment wells were set. Subsequently, 20 μl MTT (5mg/mL; Sigma, St. Louis, MO, USA) solution in sterile deionized water was added at 24, 48, and 72 h, followed by incubation for a further 4h. After termination of the reaction, the supernatant was removed and the formazan precipitate was dissolved in 150 μL DMSO (Sigma). Absorbance values at 490nm were read on a microtiter plate reader (Thermo Scientific, West Palm Beach, FL, USA). Five replicates were examined for each MTT assay. The inhibitory rate of cell proliferation was calculated according to the formula: $[1 - (\text{experimental absorbance value} - \text{zero absorbance value}) / (\text{control absorbance value} - \text{zero absorbance value})] \times 100$.

Treatment of human tumor xenograft mice

Six week-old female DBA/2 mice were obtained from Shanghai Laboratory Animal Co. (China Academy of Sciences, Shanghai, China). Animal studies were conducted in accordance with the ALAARK protocol guidelines in Tianjin GLP laboratory, China. Female DBA/2 mice (weighing 16–20 mg) were housed in barrier

facilities under a 12h light/dark cycle and supplied food and water ad libitum.

On day zero, one group was inoculated via i.p. injection with A549 tumor cells (2×10^5) in 0.5mL RPMI1640. Treatment was initiated after the tumor was allowed to grow to a volume of $\sim 100\text{mm}^3$ on the back of the mouse. This experimental protocol is intended to mimic the clinical situation whereby treatment is initiated after establishment of tumor. Animals were treated with the specified dose of quercetin or compound 2 (25mg/kg body weight) every day. During the 25-day experimental period, survival time was recorded as days after tumor injection. Mean and median survival times and statistical significance of data were determined with a two-tailed Wilcoxon's rank test. All data obtained from replicate experiments were pooled and utilized for statistical analysis.

Statistical analysis

Statistical significance was evaluated using the two-tailed Student's *t*-test. Data were considered significant at $P < 0.05$.

Results

As proposed, structural modification of quercetin improved its water solubility. Notably, water solubility of compound 2 in various buffers was significantly higher than that of quercetin, as shown in Table 1.

Data from the cellular uptake assay indicated that compound 2 is efficiently transported into A549 cells owing to increased affinity for the LAT-1 transporter (Figure 1A). The initial transport rate was 2min and reached at plateau at 15min. We observed considerably higher accumulation of compound 2 in A549 cells, compared to native quercetin (Figure 1B). According to previous findings, the \square -free carboxyl group is crucial for targeting the LAT-1 transporter. Compound 2 clearly retained LAT-1 inhibitory activity following structural modifications. More important, the compound 2 exerted a competitive inhibitory effect (Figure 1C).

The cellular MTT assay was employed to measure the anti-tumor activity of compound 2. In A549 cells overexpressing LAT-1, treatment with compound 2 resulted in significant loss of cell viability, signifying LAT-1 inhibitory activity (Table 2). To establish

Table 1: Saturating concentrations of test compounds in various solvents.

	Chemical	Solvent	Theoretical Conc (mM)	Measured Conc (mM)
Q1	quercetin	0.9% NaCl	4	9.577
Q2	compound 2			24.823
Q3	compound 3			11.354
Q1	quercetin	PBS	4	7.569
Q2	compound 2			22.158
Q3	compound 3			9.184
Q1	quercetin	Hanks pH 6.5	4	13.874
Q2	compound 2			13.321
Q3	compound 3			13.785
Q1	quercetin	Hanks – pH7.4	4	10.096
Q2	compound 2			67.244
Q3	compound 3			14.746

Table 2: MTT assay to determine the effect of compound 2 relative to quercetin on A549 tumor cells.

Time	A549	
	Quercetin	Compound 2
24h	23.01 \pm 3.16	43.75 \pm 3.32
48h	35.42 \pm 4.02	68.71 \pm 7.97
72h	46.63 \pm 3.45	84.95 \pm 5.64

Experimental conditions: Cells (1×10^5 cells/100 μ L/well) were seeded in 96-well plates under 37°C and 5% CO₂. Aqueous solutions of quercetin and compound 2 were added into the culture medium following the assay protocol.

Legend: Measurement of anti-proliferative activity of compound 2 in A549 cells with high LAT-1 transporter expression.

the effects of modified quercetin *in vivo*, A549 cell xenograft-bearing mice were treated with compound 2 and quercetin, and antitumor activities determined by monitoring tumor volumes after treatment (Figure 2). Compound 2 was administered at a dose of 8mg/kg body weight for 30 days and quercetin administered at an identical dose and frequency as control. Notably, tumor sizes of the groups treated with compound 2 were remarkably reduced, compared to mice administered quercetin alone (Figure 2A). Moreover, administration of compound 2 increased the survival rates of experimental mice, as shown in Figure 2B.

Our collective *in vitro* and *in vivo* results demonstrate that modification of quercetin via additional amino acid conjugation enhances its anti-tumor activity. The improved therapeutic benefits of modified quercetin may be attributable to both increased LAT-1 inhibitory activity and water solubility.

Conclusion

In this study, structural modification of quercetin was performed to improve its water solubility and bioavailability based on earlier literature showing that the conjugation of amino acids is capable of improving biological properties. The transporter protein, LAT-1, is overexpressed in several tumor types. Among the two compounds synthesized in this study, compound 2 exhibited enhanced therapeutic properties. The solubility of compound 2 was three-fold higher than that of quercetin, indicative of higher bioavailability for clinical utility. Moreover, compound 2 possessed LAT-1 inhibitory activity, as expected, leading to higher accumulation in tumors. The collective results support the efficacy of compound 2 as a potential anti-tumor agent. Moreover, the structural modification strategy reported in this study may be employed to optimize other therapeutic agents.

Acknowledgements

This study was supported by the National Natural Science Funding program (81771221 and 81870967).

Ethics approval and consent to participate.

All animal experiments were approved by the General Hospital of Tianjin Medical University and performed following the Guide for the Care and Use of Laboratory Animals and Stroke Treatment.

References

- Christensen HN. Role of amino acid transport and counter transport in nutrition and metabolism. *Physiol Rev.* 1990. 70: 43-77.
- Segawa H, et al. Identification and functional characterization of a Na⁺-independent neutral amino acid transporter with broad substrate selectivity. *J*

- Biol Chem. 1999; 274: 19745-19751.
3. Uchino H, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. *Mol Pharmacol*. 2002; 61: 729-737.
 4. Nawashiro H, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. *Int J Cancer*. 2006; 119: 484-492.
 5. Kaira K, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. *Br J Cancer*. 2008; 98: 742-748.
 6. Yanagida O, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. *Biochim Biophys Acta*. 2001; 1514: 291-302.
 7. Formica JV and W Regelson. Review of the biology of Quercetin and related bioflavonoids. *Food Chem Toxicol*. 1995; 33: 1061-1080.
 8. Ferry DR, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. *Clin Cancer Res*. 1996; 2: 659-668.
 9. Avila MA, et al. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. *Cancer Res*. 1994; 54: 2424-2428.
 10. Rahman A, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. *Cancer Res*. 1994; 54: 5543-5546.
 11. Gugler R, M Leschik and HJ Dengler. Disposition of quercetin in man after single oral and intravenous doses. *Eur J Clin Pharmacol*. 1975; 9: 229-234.